Active Recombinant Mouse Lefty1

• Cat.No.: Lefty1-629M
• Product Overview: Recombinant Mouse Lefty1 (Accession # NP_034224), fused with , was produced in Mouse myeloma cell line, NS0-derived.

Specification

• Source: Mammalian cells
• Species: Mouse
• Predicted N Terminal: Leu22 (pro) & His (mature)
• Form: Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein.
• Bio-activity: Measured by its ability to cause heart reversals when injected into the right or left lateral plate mesoderm of Xenopus neurulae embryos.Between 10-50 ng per embryo will cause 50% heart reversals.
• Molecular Mass: Recombinant Mouse Lefty1 has a calculated MW of 26.9 kDa. In SDS-PAGE migrates as 12 kDa and 36 kDa, reducing conditions.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Storage: Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).

Gene Information

• Gene Name: Lefty1 left right determination factor 1 [ Mus musculus ]
• Official Symbol: Lefty1
• Synonyms: LEFTY1; left right determination factor 1; left-right determination factor 1; TGF-beta-4; protein lefty-1; transforming growth factor beta-4; left-right determination, factor B; stimulated by retinoic acid gene 3 protein; Ebaf; Leftb; Stra3; Tgfb4; lefty; lefty-1; AI450052
• Gene ID: 13590
• mRNA Refseq: NM_010094
• Protein Refseq: NP_034224

Reviews

02/12/2021

The knowledgeable and experienced support team is readily available to address any questions or concerns that researchers may have throughout their experimental journey.

08/22/2018

Its stability and reliability warrant its inclusion in my research protocols, leading to meaningful and conclusive results.

10/02/2016

Their prompt and effective responses help ensure smooth and efficient progress, indeed solving any problem that arises.

Q&As

Can LEFTY1 be used in combination with other treatments?

Combination therapies involving LEFTY1 are being investigated to enhance treatment efficacy and reduce the risk of resistance development.

Are there any ongoing clinical trials involving LEFTY1?

Some clinical trials are exploring the therapeutic potential of LEFTY1, particularly in cancer treatment and tissue regeneration.

How does LEFTY1 interact with other signaling pathways in the body?

LEFTY1 interacts with various signaling pathways, influencing cellular processes involved in development, immune response, and disease progression.

How is LEFTY1 protein associated with clinical applications?

LEFTY1 has shown potential clinical applications in various fields, including cancer research and regenerative medicine.

How does LEFTY1 contribute to tissue regeneration?

LEFTY1 has demonstrated the ability to influence stem cell differentiation and tissue repair, making it a potential candidate for regenerative medicine.